Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Matthew Mattera
Institution:
Analysis Group (United States)
Observed institutions:
Analysis Group (United States),
University of Pennsylvania
ORCID:
0009-0001-4418-7263
Observed ORCID:
0009-0001-4418-7263
OpenAlex ID:
A5081873898
The surgical safety checklist and patient outcomes after surgery: a prospective observational cohort study, systematic review and meta-analysis
2017
·
T.E.F. Abbott
, T. Ahmad
, et al.
·
British Journal of Anaesthesia
·
198
Improved Quality of Recovery from Ambulatory Shoulder Surgery After Implementation of a Multimodal Perioperative Pain Management Protocol
2018
·
Nabil M Elkassabany
, Anthony Wang
, et al.
·
Pain Medicine
·
43
Prospective observational cohort study on grading the severity of postoperative complications in global surgery research
2019
·
International Surgical Outcomes Study (ISOS) group
, T E F Abbott
, et al.
·
British journal of surgery
·
36
PDF
Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
2025
·
Hans C. Lee
, Naresh Bumma
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
13
Healthcare resource use and costs among patients with COVID-19 in the United States
2025
·
Gui Liu
, Nicolae Done
, et al.
·
BMC Health Services Research
·
7
PDF
New Vaccine Platforms—Novel Dimensions of Economic and Societal Value and Their Measurement
2024
·
Philip O. Buck
, Dumingu Aparna Gomes
, et al.
·
Vaccines
·
6
PDF
Comparative Efficacy of linvoseltamab versus Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison
2025
·
Hans Lee
, Naresh Bumma
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
4
P-415 Indirect Comparison of Linvoseltamab Versus Talquetamab for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
2024
·
Joshua Richter
, Sundar Jagannath
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
4
Treatment patterns, health care resource utilization and costs, and clinical outcomes among older adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma
2025
·
Liya Wang
, Aolin Wang
, et al.
·
Journal of Managed Care & Specialty Pharmacy
·
3
Indirect comparison of linvoseltamab versus elranatamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).
2025
·
Sundar Jagannath
, Hans C. Lee
, et al.
·
Journal of Clinical Oncology
·
3
PDF
P-402 Indirect Comparison of Linvoseltamab Versus Teclistamab for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM): An Updated Analysis Based on 14-Month Follow-Up Data
2024
·
Hans Lee
, Naresh Bumma
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
3
Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).
2024
·
Sundar Jagannath
, Hans C. Lee
, et al.
·
Journal of Clinical Oncology
·
3
One size does not fit all: Qualitative interviews with individuals with overweight or obesity and healthcare providers on navigating and supporting weight management
2026
·
Fatima Cody Stanford
, Donna Mojdami
, et al.
·
Obesity Pillars
·
2
P-403 Indirect Comparison of Linvoseltamab Versus Selinexor Plus Dexamethasone for Penta-Exposed Relapsed/Refractory Multiple Myeloma (RRMM)
2024
·
Jeffrey Zonder
, Hans Lee
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
2
Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison
2026
·
Joshua Richter
, Hans C. Lee
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
1
PDF
Comparative efficacy of linvoseltamab versus teclistamab in triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM): Updated matching-adjusted indirect comparison (MAIC) with longer follow-up.
2026
·
Hans C. Lee
, Naresh Bumma
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Real-world comparison of survival with nivolumab (NIVO) + relatlimab (RELA) vs NIVO + ipilimumab (IPI) in advanced melanoma.
2025
·
Michael A. Postow
, Sekwon Jang
, et al.
·
Journal of Clinical Oncology
·
1
534. Healthcare Resource Utilization and Costs among Patients with COVID-19 in the United States
2023
·
Gui Liu
, Nicolae Done
, et al.
·
Open Forum Infectious Diseases
·
1
PDF
Attributes and Trade-Offs Impacting Contraceptive Choice: A Discrete Choice Experiment
2026
·
Vanessa Perez Patel
, Ashley Holub
, et al.
·
Patient Preference and Adherence
Long-term efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC) with 5-year follow-up data.
2026
·
Hussein A. Tawbi
, Dirk Schadendorf
, et al.
·
Journal of Clinical Oncology
E140 Perceptions of living with and managing both psoriatic disease and overweight/obesity: a qualitative interview study
2026
·
Urvi Desai
, Beth Mitchell
, et al.
·
Rheumatology
Perceptions of Living with and Managing Both Psoriatic Disease and Overweight/Obesity: A Qualitative Interview Study
2025
·
Urvi Desai
, Beth Mitchell
, et al.
·
SKIN The Journal of Cutaneous Medicine
PDF
Show more works
View as search
Works count:
22
Citation count:
331
H-index:
6
I10-index:
4
Year
Topic
Type